https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-482013-08-14 00:00:002021-11-15 14:43:30Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-752013-07-02 00:00:002021-11-15 16:56:11Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2013-04-12 17:22:322019-02-12 17:22:47Science kürt Immuntherapie gegen Krebs 2013 zum „Breakthrough of the Year“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / BioDrugs 2013 Feb;27(1):35-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-442012-04-22 00:00:002021-11-15 14:43:58Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Methods Mol. Biol. 2012;797:177-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Methods Mol. Biol. 2012;797:177-2042012-01-01 00:00:002021-11-15 16:57:22Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-982011-10-04 00:00:002021-11-15 16:58:12Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-5042011-05-09 00:00:002021-11-15 16:58:35Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-292011-03-17 00:00:002021-11-15 16:59:03Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
